Advertisement

Lymphoma

Dose-Adjusted EPOCH-R No Better Than R-CHOP in Diffuse Large B-Cell Lymphoma

Long-awaited results of the Cancer and Leukemia Group B ­(CALGB)/Alliance 50303 trial were a disappointment to many hematologists/oncologists at the 2016 American Society of Hematology...

 

Gynecologic Cancers

Is Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer?

Moore et al found that mirvetuximab soravtansine (also known as IMGN853)—an antibody-drug conjugate targeting folate receptor alpha (FRα)—is active in FRα-positive...

Symptom Management

Potential Biomarker of Recurrent Venous Thromboembolism in Cancer Patients Receiving Anticoagulant Therapy

In a biomarker analysis of the CATCH trial reported in the Journal of Clinical Oncology, Khorana et al found that elevated circulating tissue factor levels were...


Advertisement

More Top Stories

Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Results of the CheckMate 039 Trial

Cancer.Net Resource Helps Patients Manage Cancer Costs

Help your patients manage the financial impact of a cancer diagnosis with Cancer.Net’s Managing the Cost of Cancer Care booklet. This booklet provides information on key financial categories for cancer care; an easy-to-understand explanation of health insurance coverage; information about the...

Advertisement

Is Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer?

Moore et al found that mirvetuximab soravtansine (also known as IMGN853)—an antibody-drug conjugate targeting folate receptor alpha (FRα)—is active in FRα-positive platinum-resistant ovarian cancer, according to a phase I expansion cohort study reported in the Journal of...

Leukemia

Jose F. Leis, MD, PhD, and Sagar Lonial, MD, on CLL: Ibrutinib Insights

Geriatric Oncology

Co-occurrence of Cancer and Cognitive Impairment in Older Adults

The prevalence of both cancer and cognitive impairment increases with age.1-3 Based upon Surveillance, Epidemiology, and End Results (SEER)-Medicare studies, it is estimated that 3% to 7% of patients with cancer aged ≥ 65 also suffer from dementia, although the true prevalence of dementia in this ...

Leukemia

Expert Point of View: Armand Keating, MD

“This study shows that a great deal of innovation can come from existing knowledge. The 7+3 regimen has been around since I was an intern,” admitted Armand Keating, MD, of the University of Toronto and Princess Margaret Hospital, Toronto, Ontario, Canada. “Using the liposomal formulation of...

Clonal Hematopoiesis of Indeterminate Potential at Time of ASCT May Be Linked to Adverse Outcomes in Lymphoma

In a study reported in the Journal of Clinical Oncology, Gibson et al found that clonal hematopoiesis of indeterminate potential at the time of autologous stem cell transplantation (ASCT) in patients with lymphoma was associated with an increased risk of poorer outcomes.

Study Details

In the...

Breast Cancer

Diana M. Eccles, MD, on Young Breast Cancer Patients: Results From the POSH Study

2017 Oncology Meetings

JANUARY 2017

2017 Oncologic Emergency Medicine Conference
January 12-13 • Houston, Texas
For more information:
www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/oncologic-emergency-medicine-conference.html

2017 Highlights of ASH in North America

Advertisement

Identification and Characterization of HPV-Independent Cervical Cancers

A team of University of South Carolina scientists led by Carolyn Banister, PhD, and Phillip Buckhaults, PhD, identified a new subtype of cervical cancer that, like most cervical cancers, is triggered by human papillomavirus (HPV), but whose growth is not directed by the virus, suggesting that...


click me